Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Currently, several targeted therapy regimens are approved as first-line treatment in V600E/K-mutant advanced and metastatic melanoma.
|
31305324 |
2020 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We describe peripheral blood smear, bone marrow morphology, histopathology, immunohistochemistry, including BRAF V600E, and molecular testing results of patients with metastatic melanoma to the bone marrow.
|
31112348 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma-Association with Clinical Outcome and Tumor Phenotypes.
|
31835364 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we describe a patient with BRAF-V600E-positive metastatic melanoma who was sequentially treated with BRAF/MEK inhibitors (dabrafenib/trametinib) and checkpoint inhibitor immunotherapy (nivolumab, followed by pembrolizumab).
|
31082388 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF/MEK inhibition is a standard of care for patients with <i>BRAF</i> V600E/K-mutated metastatic melanoma.
|
31580757 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In contrast to metastatic melanoma, BRAF inhibition alone or in combination with mitogen-activated protein kinase kinase (MEK) inhibitors has shown little utility in the treatment of BRAF V600E-mutant mCRC.
|
31840683 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In contrast to patients with BRAF V600E-mutated metastatic melanoma, only 5% of patients with BRAF V600E-mutated mCRC responded to BRAF inhibitor monotherapy in an early-phase trial.
|
31219603 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we report a case of a 45 year-old Caucasian lady with BRAF-V600E mutant metastatic melanoma to the brain who had whole brain radiotherapy followed by two Gamma knife radiosurgery treatments for localized disease progression.
|
30972290 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
|
31415669 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with stage IV metastatic melanoma and BRAF V600E mutations (n = 11, 31-68 years of age) were included.
|
29324592 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although vemurafenib has been shown to improve the overall survival of patients with metastatic melanoma harboring the BRAF V600E mutation, its efficacy is often hampered by drug resistance acquired within a relatively short period through several distinct mechanisms.
|
30920401 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A 75-year-old male developed a swelling in his left inguinal region and was diagnosed with a metastatic melanoma, which was found to harbor a BRAF V600E mutation.
|
31260118 |
2019 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Trametinib, a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor, has demonstrated great promise in treating metastatic melanoma associated with BRAF V600E and V600K mutations; however, it also is highly associated with cutaneous adverse events (AEs).
|
30489553 |
2018 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumors from patients with BRAF wild-type (WT), V600E (class I), and L597S (class II) metastatic melanoma were used to generate patient-derived xenografts (PDX).
|
29903896 |
2018 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Methotrexate sensitizes drug-resistant metastatic melanoma cells to <i>BRAF</i> V600E inhibitors dabrafenib and encorafenib.
|
29568360 |
2018 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib is a selective inhibitor of the BRAF V600E kinase, known to be highly effective in BRAF V600E-positive metastatic melanoma.
|
30036146 |
2018 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Targeted-NGS testing is feasible and cost-affordable and provides additional potentially actionable information for patients with BRAF V600E/K negative metastatic melanoma.
|
29926184 |
2018 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib is an inhibitor of the BRAF V600E mutation which is associated with tumor responses in patients with metastatic melanoma.
|
24815010 |
2017 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
|
29076950 |
2017 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dabrafenib is an inhibitor of BRAF V600E used for treating metastatic melanoma but a majority of patients experience adverse effects.
|
28429064 |
2017 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The MEK inhibitor trametinib was approved in 2013 for the treatment of unresectable or metastatic melanoma with a BRAF V600E mutation, the most common pathogenic mutation in melanoma.
|
28861837 |
2017 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dabrafenib, a novel selective small-molecule inhibitor of BRAF, has been shown to increase overall survival in patients with unresectable metastatic melanoma harboring the BRAF V600E mutation.
|
27624900 |
2017 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Small molecules targeting aberrant RAF activity, like vemurafenib (PLX4032), are highly effective against cancers harboring the V600E BRAF mutation and are now approved for clinical use against metastatic melanoma.
|
28188228 |
2017 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma.
|
28475671 |
2017 |
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although cAMP elevation did not alter the sensitivity of metastatic melanoma cells to BRAF(V600E) and MEK inhibitors, the EPAC-RAP1 axis appears to contribute to resistance to MAPK pathway inhibition.
|
28851815 |
2017 |